var data={"title":"Acetaminophen (paracetamol) and phenylephrine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetaminophen (paracetamol) and phenylephrine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/344350?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetaminophen-paracetamol-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetaminophen (paracetamol) and phenylephrine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635727\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cetafen Cold [OTC];</li>\n      <li>Contac Cold + Flu Maximum Strength Non-Drowsy [OTC];</li>\n      <li>Mapap Sinus PE [OTC];</li>\n      <li>Robitussin Peak Cold Nasal Relief [OTC];</li>\n      <li>Sinus Pain &amp; Pressure [OTC];</li>\n      <li>Sudafed PE Pressure + Pain [OTC];</li>\n      <li>Tylenol Sinus + Headache [OTC];</li>\n      <li>Vicks DayQuil Sinex Daytime Sinus [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635731\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Decongestant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635754\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergies/common cold/hay fever:</b> Oral: <b>Note:</b> OTC dosing recommendations may vary by product and/or manufacturer. When calculating the maximum daily dose, consider all sources of acetaminophen (prescription and OTC) and all routes of administration. Do not exceed the maximum recommended daily dose. No dose adjustment required when converting between different acetaminophen formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen 325 mg/phenylephrine 5 mg: Acetaminophen 650 mg/phenylephrine 10 mg every 4 to 6 hours as needed.  Refer to product-specific labeling for maximum daily dosage (maximum dosage range: acetaminophen 2,600 to 3,250 mg/phenylephrine 40 to 50 mg per 24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acetaminophen 500 mg/phenylephrine 5 mg: Acetaminophen 1,000 mg/phenylephrine 10 mg every 4 to 6 hours as needed; maximum: acetaminophen 4,000 mg/phenylephrine 40 mg per 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635753\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergies/common cold/hay fever:</b> Children &ge;12 years and Adolescents: Oral: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635755\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30146486\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30146487\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with hepatic impairment or active liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635759\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caplet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contac Cold + Flu Maximum Strength Non Drowsy: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mapap Sinus PE, Sudafed PE Pressure + Pain: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tylenol Sinus + Headache: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, liquid filled, oral</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vicks DayQuil Sinex Daytime Sinus: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cetafen Cold: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Robitussin Peak Cold Nasal Relief: Acetaminophen 325 mg and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sinus Pain &amp; Pressure: Acetaminophen 500 mg and phenylephrine hydrochloride 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635729\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Caplet, tablet</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635757\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Swallow caplets, gelcaps, and liquid-filled capsules whole; do not crush, chew, or dissolve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635732\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Allergies/common cold/hay fever:</b> Temporary relief of symptoms (nasal congestion/pressure, sinus pain/pressure, minor aches and pain, headache, fever) associated with hay fever, other respiratory allergies, and the common cold.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635724\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Duplicate therapy issues: This product contains acetaminophen, which may be a component of combination products. Do not exceed the maximum recommended daily dose of acetaminophen.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635737\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635733\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">OTC labeling: When used for self-medication, do not use with any other drug containing acetaminophen; in combination with or within 14 days of stopping a monoamine oxidase inhibitor (MAOI); if you  are hypersensitive to acetaminophen, phenylephrine, or any component of the formulation; longer than 10 days (for pain) or 3 days (for fever). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635734\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Acetaminophen has been associated with acute liver failure, at times resulting in liver transplant and death. Hepatotoxicity is usually associated with excessive acetaminophen intake and often involves more than one product that contains acetaminophen. Do not exceed the maximum recommended daily dose (&gt;4 g daily in adults). In addition, long-term daily dosing may also result in liver damage in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Serious and potentially fatal skin reactions, including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have occurred rarely with acetaminophen use. Discontinue therapy at the first appearance of skin rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage. Avoid ethanol or limit to &lt;3 alcoholic drinks/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment or active liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; more likely to experience adverse reactions to sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosage limit: Limit acetaminophen dose from all sources &lt;4 g/day (adults).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), discontinue use and notify health care provider if pain or nasal congestion does not improve or gets worse within 7 days or are accompanied by fever; fever gets worse or lasts &gt;3 days; if any new symptoms or nervousness, dizziness, or sleeplessness occur; or if redness or swelling is present. If sore throat persists for &gt;2 days, is accompanied or followed by a fever, headache, rash, nausea, or vomiting, contact health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635744\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635743\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9232&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hepatotoxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.<b> Exceptions: </b>Amobarbital; Butabarbital; Butalbital; Methohexital; PENTobarbital; Secobarbital; Thiopental.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Acetaminophen may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Acetaminophen may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyraPONE: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Acetaminophen may increase the serum concentration of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635756\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635748\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Although not fully elucidated, the analgesic effects are believed to be due to activation of descending serotonergic inhibitory pathways in the CNS. Interactions with other nociceptive systems may be involved as well (Smith 2009). Antipyresis is produced from inhibition of the hypothalamic heat-regulating center.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine: Causes vasoconstriction of the arterioles of the nasal mucosa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5635750\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321810\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mapap Sinus Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-325 mg (24): $3.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tylenol Sinus+Headache Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-325 mg (24): $6.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46681762\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amcal Cold &amp; Flu Relief Hot Drink (AU);</li>\n      <li>Amcal Sinus Pain Relief PE (AU);</li>\n      <li>Apracur Te Decongestivo (AR);</li>\n      <li>Beechams Cold &amp; Flu Hot Lemon (MT);</li>\n      <li>Chemists' Own Sinus Pain Relief PE (AU);</li>\n      <li>Coldrex PE Phenylephrine Congestion Clear (NZ);</li>\n      <li>Coldrex PE Phenylephrine Sinus (NZ);</li>\n      <li>Coltalin-ND (HK);</li>\n      <li>Dioppex (EE, LV);</li>\n      <li>Doregrippin (DE);</li>\n      <li>Dristan Decongestivo (AR);</li>\n      <li>Flufix (CZ);</li>\n      <li>Influbene (RO);</li>\n      <li>Kroltonex (AR);</li>\n      <li>Lekadol (RO);</li>\n      <li>Lemsip (RU);</li>\n      <li>Lemsip Cold &amp; Flu (HK, SG);</li>\n      <li>Lemsip Cold &amp; Flu Lemon (AE, JO, KW, MT, QA);</li>\n      <li>Lemsip Max (GB);</li>\n      <li>Lemsip Max Cold &amp; Flu (SG);</li>\n      <li>Lemsip Max Cold &amp; Flu Blackcurrent (MT);</li>\n      <li>Lemsip Max Cold &amp; Flu Lemon (MT);</li>\n      <li>Lemsip Max Cold &amp; Flu with Decongestant Hot Drink (AU);</li>\n      <li>Mexalen Complex (AT);</li>\n      <li>Naldeflex Dia (BR);</li>\n      <li>Panadol Cold &amp; Flu (KW, QA);</li>\n      <li>Panadol Cold &amp; Flu Sinus Relief PE (QA);</li>\n      <li>Panadol Plus + Cold &amp; Flu (NZ);</li>\n      <li>Panadol Sinus Max (SG);</li>\n      <li>Panadol Sinus PE (AU);</li>\n      <li>Panadol Sinus Relief PE (NZ);</li>\n      <li>Paralen Hot Drink (CZ);</li>\n      <li>Pharmagrip Duo (ES);</li>\n      <li>Refrianex Antigrippal (AR);</li>\n      <li>Sinutab Extra (MX);</li>\n      <li>Sinutab Plus NS (PE);</li>\n      <li>Swispara (EE, LV);</li>\n      <li>Symptomed (HU);</li>\n      <li>Tempra XT DIA (MX);</li>\n      <li>Theraflu Complex Grip (PL);</li>\n      <li>Vicks Sinex (GB);</li>\n      <li>Vicks Symptomed (CZ);</li>\n      <li>Woolworths Select Cold &amp; Flu + Decongestant Hot Drink (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagheri H, Bernhard NB, and Montastruc JL, &quot;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&quot; <i>Ann Pharmacother</i>, 1999, 33(4):506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/10332548/pubmed\" target=\"_blank\" id=\"10332548\">10332548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caldeira D, Costa J, Barra M, Pinto FJ, Ferreira JJ. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. <i>Thromb Res.</i> 2015; 135(1):58-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/25456003/pubmed\" target=\"_blank\" id=\"25456003\">25456003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Contac Cold + Flu Day Non-Drowsy Maximum Strength (acetaminophen/phenylephrine) [prescribing information]. Atlanta, GA: Meda Consumer Healthcare; no date. http://www.contac.com/about-contac/contac-cold-flu-day</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &quot;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&quot; <i>J Thromb Haemost</i>, 2003, 1(4):714-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/12871405/pubmed\" target=\"_blank\" id=\"12871405\">12871405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &quot;Warfarin and Acetaminophen Interaction,&quot; <i>Pharmacotherapy</i>, 2003, 23(1):109-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/12523469/pubmed\" target=\"_blank\" id=\"12523469\">12523469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hylek EM, Heiman H, Skates SJ, et al, &quot;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&quot; <i>JAMA</i>, 1998, 279(9):657-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/9496982 /pubmed\" target=\"_blank\" id=\"9496982 \">9496982 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan D, Bartle WR, and Walker SE, &quot;The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin,&quot; <i>J Clin Pharmacol</i>, 1999, 39(1):68-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/9987702 /pubmed\" target=\"_blank\" id=\"9987702 \">9987702 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan D, Bartle WR, and Walker SE, &quot;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&quot; <i>Clin Pharmacol Ther</i>, 1995, 57:212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee WM, &quot;Drug-Induced Hepatotoxicity,&quot; <i>N Engl J Med</i>, 1995, 333(17):1118-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/7565951 /pubmed\" target=\"_blank\" id=\"7565951 \">7565951 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mapap Sinus Congestion and Pain (acetaminophen/phenylephrine) [prescribing information]. Livonia, MI: Major; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McClain CJ, Price S, Barve S, et al, &quot;Acetaminophen Hepatotoxicity: An Update,&quot; <i>Curr Gastroenterol Rep</i>, 1999, 1(1):42-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/10980926 /pubmed\" target=\"_blank\" id=\"10980926 \">10980926 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehlisch DR, Aspley S, Daniels SE, et al, &quot;Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol With Ibuprofen or Paracetamol Alone in the Management of Moderate to Severe Acute Postoperative Dental Pain in Adolescents and Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose, Two-Center, Modified Factorial Study,&quot; <i>Clin Ther</i>, 2010, 32(5):882-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/20685496/pubmed\" target=\"_blank\" id=\"20685496\">20685496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    QlearQuil Daytime Sinus and Congestion (acetaminophen/phenylephrine) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; no date.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shek KL, Chan LN, and Nutescu E, &quot;Warfarin-Acetaminophen Drug Interaction Revisited,&quot; <i>Pharmacotherapy</i>, 1999, 19(10):1153-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/10512064 /pubmed\" target=\"_blank\" id=\"10512064 \">10512064 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinus Pain &amp; Pressure tablets (acetaminophen/phenylephrine) [prescribing information]. Fort Myers, FL: Medique Products; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith HS. Potential analgesic mechanisms of acetaminophen. <i>Pain Physician</i>. 2009;12(1):269-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/19165309/pubmed\" target=\"_blank\" id=\"19165309\">19165309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka E, Yamazaki K, and Misawa S, &quot;Update: The Clinical Importance of Acetaminophen Hepatotoxicity in Nonalcoholic and Alcoholic Subjects,&quot; <i>J Clin Pharm Ther</i>, 2000, 25(5):325-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/11123483 /pubmed\" target=\"_blank\" id=\"11123483 \">11123483 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tylenol Sinus Congestion &amp; Pain tablets (acetaminophen/phenylephrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; no date. http://www.tylenol.com/products/tylenol-sinus-congestion-pain-caplets-daytime</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Bemt PM, Geven LM, Kuitert NA, et al, &quot;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&quot; <i>Pharm World Sci</i>, 2002, 24(5):201-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-phenylephrine-drug-information/abstract-text/12426965/pubmed\" target=\"_blank\" id=\"12426965\">12426965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Sinex (acetaminophen/phenylephrine) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; no date.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9232 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5635727\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5635731\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5635754\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F5635753\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5635755\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F30146486\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F30146487\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5635759\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5635729\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5635757\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5635732\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5635724\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5635737\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5635733\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5635734\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5635744\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5635743\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5635756\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5635748\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5635750\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321810\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46681762\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9232|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetaminophen-paracetamol-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">Acetaminophen (paracetamol) and phenylephrine: Patient drug information</a></li></ul></div></div>","javascript":null}